Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 4/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 6/20 | 0.42 |
| ▸ | ERN1 | O75460 | 1/20 | 0.42 |
| ▸ | CYP2E1 | P05181 | 3/20 | 0.40 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.40 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP4B1 | P13584 | 2/20 | 0.40 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.40 |
| ▸ | CYP2A7 | P20853 | 2/20 | 0.40 |
| ▸ | CYP3A7 | P24462 | 2/20 | 0.40 |
| ▸ | CYP2F1 | P24903 | 2/20 | 0.40 |
| ▸ | CYP2C18 | P33260 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1689661 | 0.79 | PDGFRB (0.47) | PDGFRBPDGFRANPC1CYP2A6ERN1 | |
| SCHEMBL16398855 | 0.76 | RXRA (0.50) | PDGFRBPDGFRANPC1CYP2A6ERN1 | |
| SCHEMBL4446638 | 0.75 | CYP2E1 (0.52) | PDGFRBPDGFRANPC1CYP2A6CYP2E1 | |
| SCHEMBL2780033 | 0.74 | CYP2A6 (0.55) | PDGFRBPDGFRANPC1CYP2A6CYP2E1 | |
| SCHEMBL1689880 | 0.73 | ERN1 (0.43) | PDGFRBPDGFRANPC1CYP2A6ERN1 | |
| SCHEMBL1689969 | 0.73 | CYP2A6 (0.42) | CYP2A6ERN1CYP2E1CYP2B6CYP3A4 | |
| SCHEMBL8352805 | 0.72 | CYP2A6 (0.67) | PDGFRBPDGFRANPC1CYP2A6CYP2B6 | |
| SCHEMBL29234155 | 0.71 | ERN1 (0.58) | PDGFRBPDGFRANPC1CYP2A6ERN1 | |
| SCHEMBL388181 | 0.70 | ALDH1A1 (0.69) | CYP2A6CYP2E1CYP2B6CYP1A1CYP1A2 | |
| SCHEMBL811852 | 0.70 | ALDH1A1 (0.59) | CYP2A6CYP2E1CYP2B6CYP1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093385-B2 | Leukotriene B4 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093385-B2 | Leukotriene B4 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093385-B2 | Leukotriene B4 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2012-01-10 | — | — | US | disclosed |
| EP-2190808-A1 | LEUKOTRIENE B4 INHIBITORS | F. Hoffmann-Roche AG (CH) | 2010-06-02 | — | — | EP | disclosed |
| WO-2009024492-A1 | LEUKOTRIENE B4 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-26 | — | — | WO | disclosed |
| US-20090054466-A1 | Leukotriene B4 Inhibitors | DOMINIQUE ROMYR | 2009-02-26 | — | — | US | disclosed |
| US-20090054466-A1 | Leukotriene B4 Inhibitors | DOMINIQUE ROMYR | 2009-02-26 | — | — | US | disclosed |
| US-20090054466-A1 | Leukotriene B4 Inhibitors | DOMINIQUE ROMYR | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054466-A1 | Leukotriene B4 Inhibitors | LTB4R2, LTB4R, LTC4S | PDGFRB 1011/4885PDGFRA 3054/4885NPC1 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.